IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 7,300 shares, a growth of 49.0% from the March 15th total of 4,900 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 0.6 days. Approximately 0.4% of the company’s stock are short sold.
IM Cannabis Stock Performance
Shares of NASDAQ:IMCC opened at $1.50 on Friday. The company has a market cap of $3.34 million, a P/E ratio of -0.44 and a beta of 1.13. IM Cannabis has a one year low of $1.30 and a one year high of $7.86. The business’s 50-day simple moving average is $1.80 and its 200 day simple moving average is $2.18. The company has a debt-to-equity ratio of 0.10, a quick ratio of 0.59 and a current ratio of 0.70.
IM Cannabis (NASDAQ:IMCC – Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.16. IM Cannabis had a negative net margin of 25.55% and a negative return on equity of 129.86%. The business had revenue of $9.27 million during the quarter, compared to the consensus estimate of $14.48 million.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Read More
- Five stocks we like better than IM Cannabis
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- Best Stocks Under $10.00
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- What is the Australian Securities Exchange (ASX)
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.